Story perspectives

Teva Recalls 580,000 Prazosin Bottles Over Cancer Risk

10/30/2025

Summary

Story summary

Teva Pharmaceuticals USA recalled 580,844 bottles of Prazosin Hydrochloride due to cancer-causing N-nitroso Prazosin impurity C and U.S. Food and Drug Administration classified the recall as Class II.
The affected capsules come in 1 mg, 2 mg, and 5 mg doses, with each bottle containing 100 to 1,000 capsules.
Teva stated no complaints have been received regarding this product and advised patients to consult pharmacists or healthcare providers for alternatives.

1 of 1

Story summary

Teva Pharmaceuticals USA recalled 580,844 bottles of Prazosin Hydrochloride due to cancer-causing N-nitroso Prazosin impurity C and U.S. Food and Drug Administration classified the recall as Class II.
The affected capsules come in 1 mg, 2 mg, and 5 mg doses, with each bottle containing 100 to 1,000 capsules.
Teva stated no complaints have been received regarding this product and advised patients to consult pharmacists or healthcare providers for alternatives.